Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.08
  • Today's Change0.05 / 0.29%
  • Shares traded650.00
  • 1 Year change+84.25%
  • Beta0.8118
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform6
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Teva Pharmaceutical Industries Ltd (ADR) have a median target of 23.00, with a high estimate of 26.00 and a low estimate of 9.00. The median estimate represents a 34.66% increase from the last price of 17.08.
High52.2%26.00
Med34.7%23.00
Low-47.3%9.00

Earnings history & estimates in USD

On Nov 06, 2024, Teva Pharmaceutical Industries Ltd (ADR) reported 3rd quarter 2024 earnings of 0.69 per share. This result was in line with the consensus of the 5 analysts following the company and exceeded last year's 3rd quarter results by 15.00%.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate+13.72%
Teva Pharmaceutical Industries Ltd (ADR) reported annual 2023 earnings of 2.56 per share on Jan 31, 2024.
Average growth rate+1.68%
More ▼

Revenue history & estimates in USD

Teva Pharmaceutical Industries Limited had 3rd quarter 2024 revenues of 4.33bn. This bettered the 4.12bn consensus of the 6 analysts covering the company. This was 18.33% above the prior year's 3rd quarter results.
Average growth rate+3.63%
Teva Pharmaceutical Industries Limited had revenues for the full year 2023 of 15.85bn. This was 6.17% above the prior year's results.
Average growth rate-1.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.